Pembrolizumab improves OS in firstline treatment for unresectable advanced pleural mesothelioma

Dr Bradbury talks to ecancer at ASCO 2023 about results her team presented from the phase 3 Canadian Cancer Trials Group IND.227/KEYNOTE-483 trial evaluating pembrolizumab plus chemotherapy as first-line treatment for patients with unresectable advanced pleural mesothelioma.

At the final analysis of the study, pembrolizumab improved overall survival, reducing the risk of death by 21% (HR=0.79 [95% CI, 0.64-0.98]; two-sided p value=0.0324), with a median OS of 17.3 months (95% CI, 14.4-21.3) versus 16.1 months (95% CI, 13.1-18.2) for chemotherapy alone.

Improvements were also shown in secondary end points PFS and ORR compared to chemotherapy alone.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php